236 related articles for article (PubMed ID: 36010557)
1. Neuro-Axonal Damage and Alteration of Blood-Brain Barrier Integrity in COVID-19 Patients.
Zingaropoli MA; Iannetta M; Piermatteo L; Pasculli P; Latronico T; Mazzuti L; Campogiani L; Duca L; Ferraguti G; De Michele M; Galardo G; Pugliese F; Antonelli G; Andreoni M; Sarmati L; Lichtner M; Turriziani O; Ceccherini-Silberstein F; Liuzzi GM; Mastroianni CM; Ciardi MR
Cells; 2022 Aug; 11(16):. PubMed ID: 36010557
[TBL] [Abstract][Full Text] [Related]
2. CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series.
Edén A; Kanberg N; Gostner J; Fuchs D; Hagberg L; Andersson LM; Lindh M; Price RW; Zetterberg H; Gisslén M
Neurology; 2021 Jan; 96(2):e294-e300. PubMed ID: 33004602
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers of Neurological Damage: From Acute Stage to Post-Acute Sequelae of COVID-19.
Zingaropoli MA; Pasculli P; Barbato C; Petrella C; Fiore M; Dominelli F; Latronico T; Ciccone F; Antonacci M; Liuzzi GM; Talarico G; Bruno G; Galardo G; Pugliese F; Lichtner M; Mastroianni CM; Minni A; Ciardi MR
Cells; 2023 Sep; 12(18):. PubMed ID: 37759493
[No Abstract] [Full Text] [Related]
4. CSF Biomarkers in COVID-19 Associated Encephalopathy and Encephalitis Predict Long-Term Outcome.
Guasp M; Muñoz-Sánchez G; Martínez-Hernández E; Santana D; Carbayo Á; Naranjo L; Bolós U; Framil M; Saiz A; Balasa M; Ruiz-García R; Sánchez-Valle R;
Front Immunol; 2022; 13():866153. PubMed ID: 35479062
[TBL] [Abstract][Full Text] [Related]
5. Neurological symptoms and axonal damage in COVID-19 survivors: are there sequelae?
Bozzetti S; Ferrari S; Zanzoni S; Alberti D; Braggio M; Carta S; Piraino F; Gabbiani D; Girelli D; Nocini R; Monaco S; Crisafulli E; Mariotto S
Immunol Res; 2021 Dec; 69(6):553-557. PubMed ID: 34363587
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity.
Virhammar J; Nääs A; Fällmar D; Cunningham JL; Klang A; Ashton NJ; Jackmann S; Westman G; Frithiof R; Blennow K; Zetterberg H; Kumlien E; Rostami E
Eur J Neurol; 2021 Oct; 28(10):3324-3331. PubMed ID: 33369818
[TBL] [Abstract][Full Text] [Related]
7. Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations.
Bonetto V; Pasetto L; Lisi I; Carbonara M; Zangari R; Ferrari E; Punzi V; Luotti S; Bottino N; Biagianti B; Moglia C; Fuda G; Gualtierotti R; Blasi F; Canetta C; Montano N; Tettamanti M; Camera G; Grimoldi M; Negro G; Rifino N; Calvo A; Brambilla P; Biroli F; Bandera A; Nobili A; Stocchetti N; Sessa M; Zanier ER
Front Immunol; 2022; 13():1070379. PubMed ID: 36591311
[TBL] [Abstract][Full Text] [Related]
8. Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms.
Edén A; Grahn A; Bremell D; Aghvanyan A; Bathala P; Fuchs D; Gostner J; Hagberg L; Kanberg N; Kanjananimmanont S; Lindh M; Misaghian S; Nilsson S; Schöll M; Sigal G; Stentoft E; Studahl M; Yilmaz A; Wang M; Stengelin M; Zetterberg H; Gisslén M
JAMA Netw Open; 2022 May; 5(5):e2213253. PubMed ID: 35604688
[TBL] [Abstract][Full Text] [Related]
9. Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological Syndromes.
Lennol MP; Ashton NJ; Moreno-Pérez O; García-Ayllón MS; Ramos-Rincon JM; Andrés M; León-Ramírez JM; Boix V; Gil J; Blennow K; Merino E; Zetterberg H; Sáez-Valero J
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769057
[TBL] [Abstract][Full Text] [Related]
10. Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection.
Hanson BA; Visvabharathy L; Ali ST; Kang AK; Patel TR; Clark JR; Lim PH; Orban ZS; Hwang SS; Mattoon D; Batra A; Liotta EM; Koralnik IJ
Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35256481
[TBL] [Abstract][Full Text] [Related]
11. Intrathecal inflammatory responses in the absence of SARS-CoV-2 nucleic acid in the CSF of COVID-19 hospitalized patients.
Normandin E; Holroyd KB; Collens SI; Shaw BM; Siddle KJ; Adams G; Rudy M; Solomon IH; Anahtar MN; Lemieux JE; Trombetta BA; Kivisakk P; Arnold SE; Rapalino O; Piantadosi AL; Sen P; Rosenberg ES; Branda J; Sabeti PC; Mukerji SS
J Neurol Sci; 2021 Nov; 430():120023. PubMed ID: 34678659
[TBL] [Abstract][Full Text] [Related]
12. Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage.
van den Bosch A; Fransen N; Mason M; Rozemuller AJ; Teunissen C; Smolders J; Huitinga I
Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35241571
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Poorly Replicates in Cells of the Human Blood-Brain Barrier Without Associated Deleterious Effects.
Constant O; Barthelemy J; Bolloré K; Tuaillon E; Gosselet F; Chable-Bessia C; Merida P; Muriaux D; Van de Perre P; Salinas S; Simonin Y
Front Immunol; 2021; 12():697329. PubMed ID: 34386007
[TBL] [Abstract][Full Text] [Related]
14. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier.
Buzhdygan TP; DeOre BJ; Baldwin-Leclair A; Bullock TA; McGary HM; Khan JA; Razmpour R; Hale JF; Galie PA; Potula R; Andrews AM; Ramirez SH
Neurobiol Dis; 2020 Dec; 146():105131. PubMed ID: 33053430
[TBL] [Abstract][Full Text] [Related]
15. Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients.
Alexopoulos H; Magira E; Bitzogli K; Kafasi N; Vlachoyiannopoulos P; Tzioufas A; Kotanidou A; Dalakas MC
Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32978291
[TBL] [Abstract][Full Text] [Related]
16. Serum neurofilament light chain levels in Covid-19 patients without major neurological manifestations.
Verde F; Milone I; Bulgarelli I; Peverelli S; Colombrita C; Maranzano A; Calcagno N; Ticozzi N; Perego GB; Parati G; Torresani E; Ratti A; Silani V
J Neurol; 2022 Nov; 269(11):5691-5701. PubMed ID: 35781535
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases are involved in the development of neurological complications in patients with Coronavirus disease 2019.
Mohammadhosayni M; Sadat Mohammadi F; Ezzatifar F; Mahdavi Gorabi A; Khosrojerdi A; Aslani S; Hemmatzadeh M; Yazdani S; Arabi M; Marofi F; Jadidi-Niaragh F; Shomali N; Mohammadi H
Int Immunopharmacol; 2021 Nov; 100():108076. PubMed ID: 34450402
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by blood-brain barrier permeability.
Kalm M; Boström M; Sandelius Å; Eriksson Y; Ek CJ; Blennow K; Björk-Eriksson T; Zetterberg H
Brain Res; 2017 Aug; 1668():12-19. PubMed ID: 28522263
[TBL] [Abstract][Full Text] [Related]
19. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up.
Kanberg N; Simrén J; Edén A; Andersson LM; Nilsson S; Ashton NJ; Sundvall PD; Nellgård B; Blennow K; Zetterberg H; Gisslén M
EBioMedicine; 2021 Aug; 70():103512. PubMed ID: 34333238
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of neurofilament light chain in the cerebrospinal fluid and blood as a biomarker for neuronal damage in experimental pneumococcal meningitis.
Le ND; Muri L; Grandgirard D; Kuhle J; Leppert D; Leib SL
J Neuroinflammation; 2020 Oct; 17(1):293. PubMed ID: 33028339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
